Journal
CA-A CANCER JOURNAL FOR CLINICIANS
Volume 66, Issue 1, Pages 75-88Publisher
WILEY
DOI: 10.3322/caac.21329
Keywords
genomics; transcriptome; neoplasm; gene fusion; patient care
Categories
Funding
- American Cancer Society [MRSG-12-194-01-TBG]
- Prostate Cancer Foundation
- Clinical Sequencing Exploratory Research (CSER) Consortium [UM1HG006508-01A1]
- FORE Cancer Research
- American Lung Association
- Pelotonia
- Novartis
- Ariad Pharmaceuticals for conducting clinical trials outside the submitted work
- Oncofusion Therapeutics
- American Cancer Society Clinical Research Professorship [CRP-14-112-06-COUN]
- Prostate Cancer Foundation [PCF351883]
- CSER Consortium [1UM1HG006508]
- National Institutes of Health Specialized Programs of Research Excellence [P50CA69568]
- Early Detection Research Network [UO1 CA113913]
- NATIONAL CANCER INSTITUTE [U01CA113913, P50CA069568, P50CA186786] Funding Source: NIH RePORTER
- NATIONAL HUMAN GENOME RESEARCH INSTITUTE [UM1HG006508] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Understanding the molecular landscape of cancer has facilitated the development of diagnostic, prognostic, and predictive biomarkers for clinical oncology. Developments in next-generation DNA sequencing technologies have increased the speed and reduced the cost of sequencing the nucleic acids of cancer cells. This has unlocked opportunities to characterize the genomic and transcriptomic landscapes of cancer for basic science research through projects like The Cancer Genome Atlas. The cancer genome includes DNA-based alterations, such as point mutations or gene duplications. The cancer transcriptome involves RNA-based alterations, including changes in messenger RNAs. Together, the genome and transcriptome can provide a comprehensive view of an individual patient's cancer that is beginning to impact real-time clinical decision-making. The authors discuss several opportunities for translating this basic science knowledge into clinical practice, including a molecular classification of cancer, heritable risk of cancer, eligibility for targeted therapies, and the development of innovative, genomic-based clinical trials. In this review, key applications and new directions are outlined for translating the cancer genome and transcriptome into patient care in the clinic. (C) 2015 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available